GLP-1s Changed Obesity Medicine—We Need to Use Them Wisely
From Gila monster venom to cardiometabolic breakthrough, GLP-1 drugs deliver remarkable benefits—but only when paired with nutrition, muscle preservation and suitable monitoring.
GLP-1 receptor agonists are among the most powerful cardiometabolic therapies ever developed
They produce substantial weight loss, improve glycemic control, and reduce cardiovascular events
Rapid pharmacologic weight loss predictably includes lean mass loss—often 25–40% without countermeasures
Muscle preservation requires adequate protein (≈1.2–1.6 g/kg/day) and resistance training
Severe appetite suppression can lead to malnutrition, micronutrient deficiencies, risk of weight rebound with decreased metabolic rate, loss of lean mass, and functional decline
These medications work best with structured monitoring and medical supervision
The story of GLP-1 receptor agonists begins in an unlikely place: the venom of the Gila monster, a lizard native to the American Southwest. What began as a curiosity of comparative physiology has become one of the most consequential therapeutic advances in modern medicine, reshaping how we treat type 2 diabetes, obesity, cardiovascular disease, sleep apnea, and potentially much more.
But with great power comes great responsibility (and possibly hype). As these medications dominate headlines and social media feeds, it’s worth taking a clear-eyed look at both their remarkable potential and their real limitations.
From Desert Venom to Blockbuster Drug
In the 1990s, researchers discovered that exendin-4, a peptide in Gila monster saliva, mimicked human glucagon-like peptide-1 (GLP-1)— a naturally occurring incretin hormone that regulates blood sugar and appetite. Unlike native GLP-1, which is rapidly degraded, exendin-4 persisted for hours, making it pharmacologically viable.
During my internal medicine residency, Dr. Josephine Egan—an endocrinologist at Johns Hopkins—often wore a small Gila monster model pinned to her lab coat. Years ago, she recognized that GLP-1 analogs represented a fundamentally new approach: targeting appetite, glycemia, potentially beta-cell mass regulation and metabolism at their shared physiologic roots. Her more recent work reviewed that there are GLP-1 receptors in the tongue, underscoring how deeply these pathways are embedded in human biology.
GLP-1 therapy has launched a pharmacologic revolution. Early agents such as exenatide were limited by dosing frequency (twice daily injections), modest efficacy, and tolerability. Newer GLP-1-based agents—semaglutide and tirzepatide most notably—offer far greater potency, durability, and clinical impact. These are no longer just “diabetes drugs”; they are cardiometabolic therapies with effects that extend well beyond glucose control. Oral formulations and next-generation multi-agonists are already expanding the landscape.
The Case For: Why GLP-1s Are Paradigm-Shifting
The benefits of GLP-1 receptor agonists are substantial and well supported.
They routinely lower A1C by 1.5–2.5% with minimal hypoglycemia risk. They produce average weight loss of 15–20% of body weight—outcomes previously achievable only through bariatric surgery. Multiple cardiovascular outcome trials demonstrate 20–26% reductions in major adverse cardiovascular events, including heart attack and stroke.
Beyond weight and glucose, GLP-1 therapy improves blood pressure, reduces liver fat (including resolution of MASH), slows progression of chronic kidney disease, and lowers systemic inflammation. Emerging data suggest effects on addiction pathways, cognition, and inflammatory disease—areas that remain investigational but biologically plausible.
The Case Against: Real Risks and Practical Limitations
These drugs are not magic bullets.
Gastrointestinal side effects—nausea, vomiting, diarrhea, constipation—are common and sometimes severe enough to cause dehydration, emergency department visits, and discontinuation. GLP-1–mediated slowing of gastric emptying is well established; whether persistent gastroparesis can occur remains controversial and under active investigation.
Perhaps one of the potentially underappreciated risk is loss of lean mass. Rapid weight loss inevitably includes muscle loss, and studies suggest that 25–40% of weight lost on GLP-1 therapy comes from lean tissue. Without countermeasures, this can impair strength, worsen frailty risk in older adults, and undermine long-term metabolic health.
Preventing Muscle Loss: What Actually Works
Muscle loss is not inevitable, but prevention requires intention:
Protein intake of approximately 1.2–1.6 g/kg/day (or 80–120 g/day absolute minimum for most patients)
Avoiding prolonged intake below ~0.4–0.5 g/kg/day, which accelerates muscle atrophy
Progressive resistance training two to three times weekly, targeting major muscle groups
Creatine combined with strength exercise may help reduce loss of muscle mass
Distributing protein across meals (≈25–30 g per meal)
Monitoring functional measures such as grip strength or sit-to-stand performance
Malnutrition, Micronutrients, and Disordered Eating
Profound appetite suppression can become a liability. Some patients consume 500–800 calories per day for prolonged periods, placing them at risk for protein-calorie malnutrition and micronutrient deficiencies.
Clinicians are increasingly seeing deficiencies in B vitamins, iron, calcium, vitamin D—and even vitamin C deficiency (scurvy)—particularly in patients who have markedly reduced intake of fruits and vegetables. Hair loss (telogen effluvium), fatigue, cold intolerance, orthostasis, and loss of subcutaneous fat (”Ozempic face,” “Ozempic breasts,” and “Ozempic buttocks”) often signal inadequate intake rather than benign side effects.
GLP-1 therapy may also cause, exacerbate, or unmask disordered eating. Appetite suppression can reinforce restrictive behaviors, particularly in individuals with current or prior eating disorders, making screening and longitudinal monitoring essential.
Rare but Serious Complications
While uncommon, several important risk signals deserve explicit discussion:
Pancreatitis: rare, but reported (~1 per 1,000 patient-years)
Gallbladder disease: increased risk of cholelithiasis and cholecystitis, particularly with rapid weight loss
Diabetic retinopathy: transient worsening with rapid glycemic improvement
Thyroid C-cell tumors: seen in rodents; human relevance appears minimal but underlies black-box warnings
Non-arteritic anterior ischemic optic neuropathy (NAION): rare reports of sudden vision loss
These risks are uncommon, but informed consent requires acknowledging them.
Monitoring and Long-Term Planning
GLP-1 receptor agonists require ongoing medical supervision. Monitoring should include:
Weight trajectory and symptom burden
Nutritional adequacy and caloric intake
Lean mass preservation (body composition when feasible; DXA as gold standard)
Functional status and strength
Surveillance for rare but serious adverse effects
Equally important is planning for the long term. Weight regain after discontinuation is common—often substantial—raising questions about duration of therapy, cost sustainability, and the risk of ending treatment with less muscle and a lower metabolic rate than before. My new practice, True Health, has the technology (DXA body composition tracking and indirect calorimetry) for more advanced monitoring and a health team to ensure optimal monitoring and outcomes. In a follow-up essay, I will review issues related to pharmaco-economics and access.
The Bottom Line
GLP-1 receptor agonists represent a genuine paradigm shift in cardiometabolic medicine. Used thoughtfully, with nutrition, resistance training, and careful monitoring, they can be life-changing. Used casually or without structure, they risk becoming expensive short-term solutions with unintended consequences.
From lizard venom to modern pharmacotherapy, GLP-1s have changed what is biologically possible. Whether they improve long-term health outcomes depends on how deliberately—and responsibly—we use them.
GLP-1 Therapy: Practical Monitoring & Muscle Preservation Checklist
Protein intake: ~1.2–1.6 g/kg/day; avoid prolonged intake <0.5 g/kg/day
Resistance training: 2–3× per week, progressive, full-body
Calories: generally ≥1,200–1,500 kcal/day for most adults
Micronutrients: multivitamin; ensure vitamin D, calcium, iron as indicated; vitamin C if fruit/vegetable intake is low
Body composition: assess lean mass when feasible (DXA or validated alternatives)
Function: monitor strength, fatigue, orthostasis, and falls risk
GI tolerance: nausea, vomiting, constipation, dehydration
Red flags: hair loss, cold intolerance, weakness, visual symptoms
Long-term plan: expectations for duration, maintenance, or discontinuation discussed upfront